Equipoise

Equipoise is one of the best-known trade names for boldenone undecylenate, a synthetic anabolic-androgenic steroid administered by intramuscular injection ^[1][2]. The molecule is an ester of boldenone, a steroid that differs from testosterone by an added double bond in its first ring, and attaching the long undecylenate fatty acid chain slows its release from the injection site, giving it a prolonged duration of action ^[1]. Once in the body the ester is cleaved to yield active boldenone, so the compound behaves as a prodrug ^[1]. It is generally described as having strong anabolic and moderate androgenic activity, with only weak estrogenic effects ^[1][2].

Boldenone and its esters were developed in the mid-twentieth century, and a human formulation was at one time marketed under the name Parenabol ^[1]. Human medical use was largely abandoned by the late 1970s ^[1]. The undecylenate ester went on to become a widely used veterinary steroid, introduced by the pharmaceutical firm Squibb under the brand name Equipoise, chiefly for use in horses ^[1].

In veterinary practice the drug has been used to support weight gain, condition, and appetite in horses ^[1]. Boldenone also features prominently in food-safety and doping science: because small amounts can arise naturally in certain animals, researchers have studied its presence and metabolism in cattle, horses, and other species in order to separate natural background levels from illicit administration ^[3]. Outside legitimate medicine it is used by some bodybuilders and athletes seeking increased muscle mass, and it is frequently identified in laboratory analyses of counterfeit and illicitly sold steroid products ^[4]. As with other anabolic steroids, any performance-related effects come with health risks, and rigorous human clinical data are limited ^[2].

Boldenone undecylenate is typically supplied as an oil-based injectable solution ^[1]. In the United States it is a Schedule III controlled substance, and it appears on the World Anti-Doping Agency's list of substances prohibited in sport ^[1]. Non-veterinary human use is generally illicit ^[1]. Reported adverse effects reflect its androgenic nature and include acne, increased body hair, deepening of the voice, and other signs of masculinization, which can be especially pronounced in women ^[1][2].

Equipoise (boldenone undecylenate) is a veterinary-origin injectable androgen not approved for human use, so its human safety data come from case reports and clinical experience rather than controlled trials. Its most notable documented effect is a pronounced rise in red blood cell production and hematocrit, which can thicken the blood and raise thrombotic and cardiovascular risk; appetite stimulation is also characteristic. It suppresses the natural testosterone axis and requires post-cycle recovery, and its long ester means suppression and detectability persist for months. Mild aromatization can produce estrogenic effects such as gynecomastia and water retention, alongside androgenic effects like acne and hair loss, plus virilization risk in women. Unfavorable lipid shifts and blood pressure elevation add to the cardiovascular caution.

Equipoise is the veterinary trade name for boldenone undecylenate, an anabolic steroid first synthesized by Ciba in the 1950s during work that attached various esters to the boldenone molecule to lengthen its action. Boldenone was briefly marketed for human use under the brand name Parenabol, which was trialed in the late 1960s and early 1970s for wasting conditions and osteoporosis before being discontinued. Squibb later acquired the patents and reintroduced the undecylenate ester as Equipoise, aimed primarily at horses and cattle, where it was conceived as a long-acting injectable analog of Dianabol. Never approved for people, it migrated into bodybuilding as a widely used underground and grey-market performance steroid.